- Trials with a EudraCT protocol (2,289)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (77)
2,289 result(s) found for: Adjuvant.
Displaying page 1 of 115.
EudraCT Number: 2013-003839-30 | Sponsor Protocol Number: D081CC00006 | Start Date*: 2014-06-16 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germl... | |||||||||||||
Medical condition: Adjuvant breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing) HU (Trial now transitioned) IT (Ongoing) BE (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) NL (Ongoing) AT (Trial now transitioned) IS (Ongoing) PL (Trial now transitioned) PT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005181-30 | Sponsor Protocol Number: AFT-05/ABCSG-42/BIG_14-03 | Start Date*: 2015-07-09 | |||||||||||
Sponsor Name:ABCSG GmbH | |||||||||||||
Full Title: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor... | |||||||||||||
Medical condition: To determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) ES (Ongoing) IE (Ongoing) HU (Ongoing) PT (Ongoing) DE (Ongoing) SE (Ongoing) NL (Ongoing) BE (Ongoing) PL (Ongoing) GB (GB - no longer in EU/EEA) IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005350-79 | Sponsor Protocol Number: NN028-1801 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A single arm, single-centre, open-label, exploratory trial of recombinant Interleukin-21 administered subcutaneously for 4 weeks as neo-adjuvant treatment prior to sentinel lymph node/complete lymp... | |||||||||||||
Medical condition: Recombinant Interleukin-21 administered subcutaneously for 4 weeks as neo-adjuvant treatment prior to sentinel lymph node/complete lymph node dissection followed by 8 weeks of adjuvant treatment in... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020480-21 | Sponsor Protocol Number: pro-duct001 | Start Date*: 2010-11-18 |
Sponsor Name:Universitätsmedizin Charite | ||
Full Title: Feasibility and efficacy of adjuvant gemcitabine chemotherapy after liver transplantation for proximal bile duct cancer | ||
Medical condition: proximal bile duct cancer | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-000566-38 | Sponsor Protocol Number: R2810-ONC-1788 | Start Date*: 2019-10-04 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | |||||||||||||
Medical condition: Patients with features associated with high-risk of recurrent CSCC disease, who have completed surgery and post-operative RT radiation therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Ongoing) FR (Ongoing) GR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002079-17 | Sponsor Protocol Number: ICO-N-2017-14 | Start Date*: 2018-10-16 | |||||||||||
Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST | |||||||||||||
Full Title: Evaluation of the 64Cu-ATSM PET-CT as a predictor of the response to neo-adjuvant treatment in locally advanced rectal cancers | |||||||||||||
Medical condition: men and / or women older than 18, newly diagnosed for locally advanced rectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000129-28 | Sponsor Protocol Number: GO42784 | Start Date*: 2021-08-09 | |||||||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||||||||||||
Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WIT... | |||||||||||||||||||||||
Medical condition: Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: SE (Ongoing) SK (Ongoing) BE (Ongoing) FI (Ongoing) CZ (Ongoing) GR (Ongoing) AT (Ongoing) PT (Ongoing) PL (Ongoing) ES (Ongoing) LV (Ongoing) NL (Ongoing) IT (Ongoing) SI (Ongoing) BG (Ongoing) HR (Ongoing) RO (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004362-26 | Sponsor Protocol Number: I3Y-MC-JPCF | Start Date*: 2017-08-14 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High-Risk, Node-Positive, ... | |||||||||||||
Medical condition: Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) HU (Ongoing) GB (GB - no longer in EU/EEA) BE (Ongoing) DK (Trial now transitioned) FI (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) CZ (Ongoing) FR (Ongoing) PT (Trial now transitioned) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001908-17 | Sponsor Protocol Number: 2021.40 | Start Date*: 2022-09-05 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Neo- and adjuvant targeted therapy in BRAF-mutated anaplastic cancer of the thyroid (NEO-ATACT study) | |||||||||||||
Medical condition: BRAF-mutated anaplastic thyroid cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000575-27 | Sponsor Protocol Number: MK-3475-091-05 | Start Date*: 2015-09-17 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy... | |||||||||||||
Medical condition: Stage IB (T ≥ 4 cm), II and IIIA NSCLC | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Ongoing) SI (Ongoing) GB (GB - no longer in EU/EEA) DE (Ongoing) ES (Ongoing) EE (Ongoing) HU (Ongoing) PT (Ongoing) BE (Ongoing) AT (Ongoing) NL (Ongoing) DK (Ongoing) GR (Ongoing) LV (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002701-11 | Sponsor Protocol Number: ACE | Start Date*: 2016-06-13 |
Sponsor Name:Oslo University Hospital | ||
Full Title: ADJUVANT CHEMOTHERAPY IN ELDERLY – GERIATRIC ASSESSMENT AND PROGNOSTIC GENE SIGNATURES | ||
Medical condition: undergone R0-resection of for colon cancer stage III | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-005322-19 | Sponsor Protocol Number: MIND-DC | Start Date*: 2016-01-21 |
Sponsor Name:Radboud University Nijmegen Medical Centre | ||
Full Title: A randomized, double-blind, placebo-controlled phase III study to evaluate active immunization in adjuvant therapy of patients with stage IIIB and IIIC melanoma with natural dendritic cells pulsed ... | ||
Medical condition: melanoma patients with regional lymph node metastases (stage III) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-004455-29 | Sponsor Protocol Number: 112115 | Start Date*: 2008-12-05 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase II, randomized, multicentre, observer-blind study to compare and characterize the immunoginicity and safety parameters induced by various GSK Biologicals’ Adjuvant Systems in combination wi... | ||
Medical condition: Hepatitis B surface antigen (HBsAg) vaccine administred in HBV naïve adult subjects aged between 18 and 45 years old, inclusive, in good general health. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-003739-22 | Sponsor Protocol Number: GAL-01-2007 | Start Date*: 2007-10-04 | |||||||||||
Sponsor Name:GALSOR S.R.L. | |||||||||||||
Full Title: Safety and efficacy (for the symptom remission) of the treatment adjuvant of the antibiotic therapy of the acute episode of sinusitis (acute, subacute, chronic)with Ecballium Elaterium (SINUclean D... | |||||||||||||
Medical condition: Acute sinusitis or exacerbation of subacute or chronic sinusitis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000935-15 | Sponsor Protocol Number: PRODIGE70-CIRCULATE | Start Date*: 2019-09-10 |
Sponsor Name:Centre Hospitalier Universitaire (CHU) de Dijon | ||
Full Title: CIRCULATE- CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II | ||
Medical condition: stage II colon cancer, after tumour resection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003064-27 | Sponsor Protocol Number: PH-L19IL2TNF-01/18 | Start Date*: 2022-02-25 | |||||||||||
Sponsor Name:Philogen S.p.A. | |||||||||||||
Full Title: An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and ... | |||||||||||||
Medical condition: Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002346-33 | Sponsor Protocol Number: MO43110 | Start Date*: 2022-05-17 |
Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd | ||
Full Title: A PHASE IIIB, MULTINATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE PATIENT PREFERENCE FOR HOME ADMINISTRATION OF FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR SUBCUTANEOU... | ||
Medical condition: Early or locally advanced/inflammatory HER2-positive (HER2+) breast cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) BG (Ongoing) HR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-007345-31 | Sponsor Protocol Number: 3144A2-3004-WW | Start Date*: 2009-08-05 | |||||||||||
Sponsor Name:Puma Biotechnology, Inc | |||||||||||||
Full Title: A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer. | |||||||||||||
Medical condition: Her2 overexpressed, early stage breast cancer (adjuvant treatment stage) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) IT (Completed) SK (Completed) CZ (Completed) ES (Completed) BE (Completed) GB (Completed) LT (Completed) NL (Completed) FR (Completed) DK (Completed) SE (Completed) GR (Completed) MT (Completed) BG (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004273-27 | Sponsor Protocol Number: CUETO1801 | Start Date*: 2019-04-08 | |||||||||||
Sponsor Name:PRESURGY, S. | |||||||||||||
Full Title: Multicenter clinical trial with medical device associated with a drug in an authorised therapeutic use for the treatment of CVNMI evaluating the efficacy and tolerability of the adyuvant treatment ... | |||||||||||||
Medical condition: bladder cancer non muscle invasive in high risk patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001488-60 | Sponsor Protocol Number: WSG-AM11 | Start Date*: 2020-07-09 |
Sponsor Name:Westdeutsche Studiengruppe GmbH | ||
Full Title: A randomized, controlled, open-label, phase-III trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus stand... | ||
Medical condition: HR+/HER2- early breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.